A Phase II Study of TLK 286 [canfosfamide; TELCYTA; Telik] in Platinum Resistant Advanced Epithelial Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2013
At a glance
- Drugs Canfosfamide (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Feb 2010 Actual end date (April 2004) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.